RNA-sequencing of LNCaP prostate cancer cells with and without treatment of darolutamide
RNA-seq (gene expression) · human · 15 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Topic
- Prostate cancerThis series is part of our curated briefing on it.
- Samples
- 15 samples: 10 × LNCaP_R1881_DMSO_22h vs 5 × LNCaP_R1881_Darolutamide_22hGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Darolutamide in Combination with Radium-223 Exhibits Synergistic Antitumor Efficacy in LNCaP Prostate Cancer ModelsInternational journal of molecular sciences · 2024
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE280187_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1176846 and SRA study SRP540483. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 15 samples.
How we read this: 2 replicated groups read from 15 sample titles; they account for 15 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8591286 LNCaP_R1881_Darolutamide_22h rep1 LNCaP_R1881_Darolutamid…
- GSM8591287 LNCaP_R1881_DMSO_22h rep1 LNCaP_R1881_DMSO_22h
- GSM8591288 LNCaP_R1881_DMSO_22h rep2 LNCaP_R1881_DMSO_22h
- GSM8591289 LNCaP_R1881_DMSO_22h rep3 LNCaP_R1881_DMSO_22h
- GSM8591290 LNCaP_R1881_DMSO_22h rep4 LNCaP_R1881_DMSO_22h
- GSM8591291 LNCaP_R1881_DMSO_22h rep5 LNCaP_R1881_DMSO_22h
- GSM8591292 LNCaP_R1881_DMSO_22h rep6 LNCaP_R1881_DMSO_22h
- GSM8591293 LNCaP_R1881_DMSO_22h rep7 LNCaP_R1881_DMSO_22h
- GSM8591294 LNCaP_R1881_Darolutamide_22h rep2 LNCaP_R1881_Darolutamid…
- GSM8591295 LNCaP_R1881_Darolutamide_22h rep3 LNCaP_R1881_Darolutamid…
- GSM8591296 LNCaP_R1881_DMSO_22h rep8 LNCaP_R1881_DMSO_22h
- GSM8591297 LNCaP_R1881_Darolutamide_22h rep4 LNCaP_R1881_Darolutamid…
- GSM8591298 LNCaP_R1881_DMSO_22h rep9 LNCaP_R1881_DMSO_22h
- GSM8591299 LNCaP_R1881_Darolutamide_22h rep5 LNCaP_R1881_Darolutamid…
- GSM8591300 LNCaP_R1881_DMSO_22h rep10 LNCaP_R1881_DMSO_22h
- GSE120181 Human prostate cancer cell line, 22Rv1: Control vs. luteolin treatment 2 samples same disease briefing · shares treatment, prostate
- GSE115501 RNA sequencing on circulating tumor cells from prostate cancer patients 136 samples same disease briefing · shares prostate
- GSE222467 The RNA binding proteins LARP4A and LARP4B promote tumour growth and metastasis in prostate cancer and osteosarcoma 12 samples same disease briefing · shares prostate
- GSE300947 A novel six-biomarker panel identified from male breast cancer-associated fibroblasts demonstrates prognostic power for prostate tumors 6 samples same disease briefing · shares prostate
- GSE242541 ONECUT2 is a druggable driver of luminal to basal breast cancer plasticity 12 samples same disease briefing
- GSE71008 Plasma extracellular RNA profiles in healthy and cancer patients 192 samples same disease briefing
- GSE264573 Single Cell Analysis of Treatment–Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies 4 samples shares treatment, prostate
- GSE288843 Multiomic assessments of LNCaP and derived cell strains reveal determinants of prostate cancer pathobiology (ATAC-Seq) 30 samples shares prostate, lncap
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.